ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 127 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $353,995 | +1113.1% | 51,678 | +1736.5% | 0.00% | – |
| Q2 2023 | $29,182 | +77.4% | 2,814 | +38.4% | 0.00% | – |
| Q1 2023 | $16,447 | -56.6% | 2,033 | -15.5% | 0.00% | – |
| Q4 2022 | $37,895 | -15.8% | 2,406 | -16.2% | 0.00% | – |
| Q3 2022 | $45,000 | +32.4% | 2,871 | +19.3% | 0.00% | – |
| Q2 2022 | $34,000 | +17.2% | 2,406 | +41.4% | 0.00% | – |
| Q1 2022 | $29,000 | -95.7% | 1,702 | -96.3% | 0.00% | – |
| Q4 2021 | $671,000 | +2136.7% | 46,188 | +2699.3% | 0.00% | – |
| Q3 2021 | $30,000 | -84.9% | 1,650 | -85.4% | 0.00% | – |
| Q2 2021 | $199,000 | -46.5% | 11,299 | -23.5% | 0.00% | – |
| Q1 2021 | $372,000 | +4550.0% | 14,766 | +1030.6% | 0.00% | – |
| Q4 2020 | $8,000 | -38.5% | 1,306 | -74.0% | 0.00% | – |
| Q3 2020 | $13,000 | +1200.0% | 5,016 | +817.0% | 0.00% | – |
| Q2 2020 | $1,000 | -95.0% | 547 | -97.1% | 0.00% | – |
| Q1 2020 | $20,000 | -71.8% | 18,997 | -49.8% | 0.00% | – |
| Q4 2019 | $71,000 | +610.0% | 37,806 | +317.4% | 0.00% | – |
| Q3 2019 | $10,000 | -99.6% | 9,057 | -99.1% | 0.00% | -100.0% |
| Q2 2019 | $2,233,000 | -45.5% | 1,019,552 | +49.2% | 0.00% | -50.0% |
| Q1 2019 | $4,094,000 | -57.9% | 683,539 | -48.1% | 0.00% | -50.0% |
| Q4 2018 | $9,734,000 | – | 1,317,260 | +6932847.4% | 0.00% | – |
| Q3 2018 | $0 | – | 19 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 19 | -99.2% | 0.00% | – |
| Q1 2018 | $43,000 | -34.8% | 2,433 | -9.7% | 0.00% | – |
| Q4 2017 | $66,000 | -57.7% | 2,693 | -55.5% | 0.00% | – |
| Q3 2017 | $156,000 | +73.3% | 6,055 | +84.2% | 0.00% | – |
| Q2 2017 | $90,000 | -32.3% | 3,287 | -26.3% | 0.00% | – |
| Q1 2017 | $133,000 | +77.3% | 4,462 | +60.4% | 0.00% | – |
| Q4 2016 | $75,000 | +33.9% | 2,781 | +26.2% | 0.00% | – |
| Q3 2016 | $56,000 | +229.4% | 2,203 | +134.1% | 0.00% | – |
| Q2 2016 | $17,000 | +41.7% | 941 | +48.7% | 0.00% | – |
| Q1 2016 | $12,000 | +300.0% | 633 | +480.7% | 0.00% | – |
| Q4 2015 | $3,000 | – | 109 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |